A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Overview

The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.

Full Title of Study: “A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2009

Interventions

  • Drug: XL019
    • XL019 capsules administered orally

Arms, Groups and Cohorts

  • Experimental: 1

Clinical Trial Outcome Measures

Primary Measures

  • Safety and tolerability of XL019 as a single agent when orally administered in adults with Polycythemia Vera (PV)
    • Time Frame: Assessed at each visit
  • Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) for XL019
    • Time Frame: Assessed at periodic visits

Secondary Measures

  • Evaluate pharmacokinetic and pharmacodynamic parameters of XL019 in adults with PV
    • Time Frame: Assessed during periodic visits
  • Evaluate preliminary efficacy of XL019
    • Time Frame: Assessed weekly or bi-weekly

Participating in This Clinical Trial

Inclusion Criteria

  • The subject has a diagnosis of polycythemia vera (PV), and has failed, or is intolerant of, standard therapies or refuses to take standard medications. – The subject is ≥18 years old. – The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. – The subject has adequate organ function. – Subjects who have received phlebotomy due to PV must have documented phlebotomy history for 12 weeks prior to enrollment. – The subject has the capability of understanding the informed consent document and has signed the informed consent document. – Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study. – Female subjects of childbearing potential must have a negative pregnancy test at screening. – The subject has had no other diagnosis of malignancy or evidence of other malignancey for 2 years prior to screening for this study (except non-melanoma skin cancer or in situ carcinoma of the cervix). Exclusion Criteria:

  • The subject has received treatment for PV within 14 days prior to first dose of XL019 – The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within 3 months, or cardiac arrhythmias. – The subject is pregnant or breastfeeding. – The subject is known to be positive for the human immunodeficiency virus (HIV). – The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Exelixis
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.